Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.
[Symptoms of obsessive-compulsive disorder in neurological diseases].
Monooxygenase substrates mimic flavin to catalyze cofactorless oxygenations.
Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis.
TLR4 Deficiency Impairs Oligodendrocyte Formation in the Injured Spinal Cord.
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Cytokine regulation by modulation of the NMDA receptor on astrocytes.
Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Therapy with Eculizumab for Patients with CD59 p.Cys89Tyr Mutation.
Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis.
Human Aquaporin-4 and Molecular Modeling: Historical Perspective and View to the Future.
Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion.
Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results.
Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases.
Acute inflammatory demyelinating polyradiculoneuropathy in a newborn infant.
Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry.
Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation.
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy.
IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine.
Erratum to: 'Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia'.
Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.
Clinical Utility of Mindfulness Training in the Treatment of Fatigue After Stroke, Traumatic Brain Injury and Multiple Sclerosis: A Systematic Literature Review and Meta-analysis.
Anti-ganglioside antibodies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients.
Pages
« first
‹ previous
…
831
832
833
834
835
836
837
838
839
…
next ›
last »